[End-stage chronic renal failure in myeloma: results of dialysis].
Nowadays, maintenance dialysis can be proposed to patients suffering from myeloma with end-stage chronic renal failure. We report here data from eight patients dialysed either by hemo- (6) or peritoneal dialysis (2), together with chemotherapy in half of them. Six patients died; the longest survival has been about 6 years. The main cause of morbidity was sepsis, especially in peritoneal dialysis patients; therefore we now favour hemodialysis in patients exposed to aggressive chemotherapy. We think dialysis justified in all cases, including those with high tumor mass, in order to expect the effect of chemotherapy; then, provided good response to drugs, further survival can be consistently improved. Once on maintenance dialysis, main drawbacks for these patients are cardiovascular complications (AL amyloidosis) and above all anemia; the latter however can be markedly improved, thanks to erythropoietin therapy which provides these patients with much better quality of life.
Duvic
C
C
Service de néphrologie, hôpital Tenon, Paris, France.
Viron
B
B
Michel
C
C
Mignon
F
F
D000368:Aged; D000369:Aged, 80 and over; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007239:Infections / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D010530:Peritoneal Dialysis / Q000009:adverse effects; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects; D012189:Retrospective Studies
D004921:Erythropoietin
Insuffisance rénale chronique terminale du myélome: résultats de l'épuration extrarénale.